investors-2019-new

Investor Overview

We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable medicines. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability, positioning us well to maximise the value we create for our business and its diverse stakeholders.

We supply medicines to more than 150 countries and have 70 established business operations in 55 countries. We focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets.

FAST FACTS

OUR INVESTMENT CASE

Leveraging our strengths and capabilities to deliver long-term shareholder value, while living the Aspen values.

Please click on a title below left for more information.
Responsible corporate citizen and a trusted partner

Responsible corporate citizen and a trusted partner

  • We are committed to effective and robust corporate governance making us a trusted partner. Recent high profile corporate challenges have further heightened our attention to governance and we remain committed to continuously improving our reporting, transparency and disclosure.
  • We are a signatory to the United Nations Global Compact ("UN Global Compact") Initiative.
  • A constituent of the FTSE/JSE Responsible Investment Index.
Strategically relevant manufacturing capital
Global footprint with a focus on emerging markets
Diverse, branded product portfolio
Committed management team, strongly aligned with shareholders' interests

SENS ANNOUNCEMENTS

SHARE PRICE CENTRE

View share price information for Aspen Holdings.

SHARE CODE

APN ISIN: ZAE 000066692

JSE data delayed by 15 minutes, page refreshes every 5 minutes. Indicated trade times are actual.

PRESENTATIONS

Aspen's Year End Results presentation for the year ended 30 June 2019
PDF 1.08MB

 

CAPITAL DISTRIBUTIONS

All capital distributions to date

SHAREHOLDER STATISTICS

Analysis of shareholders at 30 June 2019

CORPORATE INFORMATION

All corporate information and contact details

CONTACT DETAILS

Luresha Chetty
+27 31 580 8637
InvestorRelations@aspenpharma.com

WEBCAST

Click here to view the webcast of Aspen's year end results presentation for the year ended 30 June 2019.

INVESTOR CALENDAR

14-15 November 2019

SA Tomorrow Conference, New York

2 December 2019

J.P. Morgan Cazenove’s South Africa Opportunities Conference
Attendee: Luresha Chetty – Investor Relations and Corporate Affairs Executive

5 December 2019

Annual General Meeting

5 March 2020

Interim results announcement for the six months ended 31 December 2019

6 March 2020

Interim results presentation in Cape Town

30 June 2020

Financial year end